A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BRC / bromocriptine

[Related PubMed/MEDLINE]
Total Number of Papers: 103
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BRC  (>> Co-occurring Abbreviation)
Long Form:   bromocriptine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively. CAB
2019 Giant Prolactinomas: Outcomes of Multimodal Treatments for 42 Cases with Long-Term Follow-Up. ---
2019 Management of Dopamine Agonist-Resistant Prolactinoma. CAB
2018 Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review. CAB, PRL, VFD
2017 Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas. RAPA
2017 Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines. ART, DAs
2016 Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup. DAs, IGPs
2016 Novel antiviral activity of bromocriptine against dengue virus replication. DENV
2015 Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. DAs, PRL
10  2015 Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience. CAB, DAs
11  2014 Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. CS NPs, i.n, NPs
12  2014 Prolactinomas, cabergoline, and pregnancy. CAB, DA
13  2013 Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. CS-NPs, i.n, i.v, PD
14  2013 Differential morphological effects in rat corpora lutea among ethylene glycol monomethyl ether, atrazine, and bromocriptine. CL, CL-E, CL-V, EGME
15  2012 A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. CBG, CTR, MI, Tri, VHD
16  2011 Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells. OCT, PRL, SSTRs
17  2011 Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. ALS, ATF3, HO-1, iNOS, LPS, NAIP, TNF
18  2009 Dopamine-regulated adrenocorticotropic hormone secretion in lactating rats: functional plasticity of melanotropes. ACTH, alpha-MPT, alpha-MSH, DOM, IL, NEDA, POMC
19  2009 Long-term treatment with bromocriptine inhibits endometrial adenocarcinoma development in rats. ENNG, PRL
20  2008 Involvement of bone morphogenetic protein-4 in GH regulation by octreotide and bromocriptine in rat pituitary GH3 cells. ALK, BMP, OCT
21  2008 Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. CAB, DAA, PRL, PRLoma
22  2008 [The assessment of the mental state of patients during simultaneous treatment with psychotropic drugs, antipsychotics included, and bromocriptine]. CGI, HDRS, PANSS, PANSS
23  2007 Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. PRL, PRM, SLE
24  2007 Effect of aluminium on duodenal calcium transport in pregnant and lactating rats treated with bromocriptine. Al, Ca, PRL
25  2006 Dopamine and nitric oxide interaction on the modulation of prepulse inhibition of the acoustic startle response in the Wistar rat. AMPH, APO, DA, L-NOARG, NO, PPI, QNP
26  2006 Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice. HPE, MPTP
27  2006 Macroprolactinemia in childhood and adolescence: a cause of hyperprolactinemia. PRL
28  2005 Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. DA, LI, PRL
29  2005 Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. PRL, VFD
30  2005 [Dopamine-agonist resistant prolactinomas: diagnosis and management]. CBG, DA, PRL
31  2003 Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. FMD, hs-CRP
32  2003 PRL-secreting pituitary adenomas in pregnancy. ---
33  2003 The role of prolactin in the prostatic inflammatory response to neonatal estrogen. PRL
34  2003 Transdermal administration of bromocriptine. CH, G-SP215, ST
35  2002 Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. ---
36  2002 Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. MAC, MIC, PRL
37  2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. CAB
38  2001 [Change of prolactin in SD rats with experimental autoimmune thyroiditis]. EAT, PRL
39  2000 Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. CAB
40  2000 Suppression of adjuvant arthritis in rats with chronic bromocriptine treatment does not prevent associated oxidative stress. AA, BRC-C, CORT, PRL, TBARS
41  1999 Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. PRL
42  1998 Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. PRL, SLE, SLEDAI
43  1998 Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. CAB, NPT, PRL
44  1998 Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. ---
45  1998 [Effects of bromocriptine in patients with active rheumatoid arthritis]. PRL, RA
46  1997 Prolactin modulation of nitric oxide and TNF-alpha production by peripheral neutrophils in rats. L-NAME, NO, oPRL, PRL, TNF-alpha
47  1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. CAB
48  1997 [Bromocriptine for refractory rheumatoid arthritis]. PRL, RA
49  1996 Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity. GH
50  1996 Role of the pituitary in tumor promotion with ethinyl estradiol in rat liver. DEN, EE, ER, GHR, HCC, mRNA, PRL
51  1996 RU486-treated rats show endocrine and morphological responses to therapies analogous to responses of women with polycystic ovary syndrome treated with similar therapies. FLU, hFSH, LHRH-A, oLH, PCO, PRL, TMX
52  1995 Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. PAPS, SLE
53  1995 Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. ---
54  1995 Modulation of cholesteryl ester hydrolase messenger ribonucleic acid levels, protein levels, and activity in the rat corpus luteum. CEH, CL, HSL, PGF2 alpha, PRL
55  1995 Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies. 5-HIAA, 5-HT, DA, DOPAC, HVA
56  1994 Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. CsA, MLR, PRL
57  1993 Bromocriptine effects on plasma luteinizing hormone and its responses to gonadotropin-releasing hormone in normal men. GnRH, LH
58  1993 Changes in brain catecholamine metabolism during bromocriptine treatment in polycystic ovary syndrome. DA, DOPAC, HVA, MHPG, PCO
59  1993 Effect of plasma prolactin on sweat rate and sweat composition during exercise in men. PRL
60  1993 Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro. PRL
61  1992 Bromocriptine and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone. PRTH, STI
62  1992 Clinical management of prolactinomas: a ten-year experience. mP, MP
63  1992 Combined therapy with bromocriptine and clomiphene citrate for patients with normoprolactinemic amenorrhea. Cl, PRL
64  1992 Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. NK
65  1992 Role of sympathetic nerve inhibition in the vasodepressor effect of bromocriptine in normotensive and hypertensive rats. NE, SHR, WKY
66  1992 Usefulness of CV 205-502 in a case of allergy to ergot-derived drugs. PRL
67  1992 [Immediate efficacy of bromocriptine (BrC)-LAR in the treatment of macroprolactinomas: apropos of a case]. ---
68  1991 Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice. APO, BUP
69  1991 Effects of pirenzepine, bromocriptine and their association on basal and GHRH- and TRH-induced GH secretion in acromegaly. PZ
70  1990 Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine. DOPAC, HVA
71  1990 Bromocriptine induces climbing behaviour: possible D-1 or D-2 dopamine receptor involvement. AMPT, APO
72  1990 Bromocriptine-induced rotation: characterization using a striatal efferent lesion in the mouse. AMPT
73  1990 Changes in saline and water intakes in bromocriptine-treated genetically hypertensive and normotensive rats. GH, NT
74  1990 Plasma and pituitary thyroid-stimulating hormone and their responses to bromocriptine in the Japanese strains of hypertensive and normotensive rats and the F2 generation of the hybrid. BP, SHR, TSH, WKY
75  1989 Aggravation of inappropriate luteinizing hormone secretion by bromocriptine in polycystic ovary syndrome with elevated serum dehydroepiandrosterone sulfate. DHAS, PCOS
76  1989 Blood pressure, plasma and pituitary prolactin responses to bromocriptine in New Zealand genetically hypertensive and normotensive rats. BP, GHR, NT, PRL
77  1988 Blood pressure, plasma and pituitary prolactin levels and their responses to bromocriptine in the segregating F2 generation of the SHR/WKY hybrid. BP, PRL, SHR, WKY
78  1988 Estradiol involvement in the luteolytic action of LH during the estrous cycle in the rat. PRL
79  1988 Further studies on the interaction between bromocriptine and SKF38393 in reserpine and alpha methyl-para-tyrosine-treated mice. AMPT, DA
80  1988 Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning. physostigmine yawning, pilocarpine yawning
81  1988 The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats. alpha-MPT
82  1988 [Combined therapy with bromocriptine, clomiphene and gonadotropin for polycystic ovary syndrome patients failing to respond to clomiphene alone]. Cl, PCOS, PRL
83  1987 Dihydroergocriptine in management of microprolactinomas. DHECP
84  1987 Investigations on the possible involvement of the dopaminergic system in the modulation of the growth and steroidogenic capacity of the rat adrenal zona glomerulosa: a coupled morphometric and biochemical study. AII, MTC
85  1987 Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. SMS
86  1987 Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. ---
87  1987 [Study on the neuroendocrinological control of prolactin release in early puerperium]. MCP, PRL
88  1986 T-cell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment. ---
89  1986 Testosterone-induced oestrous cycle blockade in the rat: no evidence for prolactin involvement. PRL, TP
90  1985 Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. ---
91  1985 Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties. AMPT
92  1985 Immunomodulation in rats by transplantable anterior pituitary tumors. DNCB
93  1985 [Effect of dopaminergic agents on the endocrine profile in labor and early puerperium]. MCP, PRL
94  1984 Bromocriptine and genetic hypertension development in young spontaneously hypertensive rats. GHD, SHRs
95  1984 Does corpus luteum function autonomously during estrous cycle in the rat? A possible involvement of LH and prolactin. ---
96  1984 Prolactin and the control of cycle length in the female rat. ---
97  1984 The prolactin-releasing mechanism of the hypothalamo-pituitary axis in pregnancy. MCP, PRL, TRH
98  1983 Immunomodulation by bromocriptine. DNCB, GH, PRL
99  1983 [Hyperprolactinemia in chronic renal insufficiency: an interesting model of hypothalamo-hypophyseal dysfunction]. CRF
100  1982 Effects of bromocriptine on single nephron and whole-kidney function in rats. GFR